Sensei Biotherapeutics (SNSE)
(Delayed Data from NSDQ)
$0.54 USD
+0.04 (8.00%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Sensei Biotherapeutics, Inc. [SNSE]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Dose Expansion Phase 1 Data for SNS-101 Expected in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Abstract Data From Phase 1 Dose Escalation Study of SNS-101 in Advanced Solid Tumors May Be Underappreciated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; Topline Data for SNS-101 Phase 1 Dose Escalation Expected at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY23 Results; Faster Than Projected Enrollment Leads to Earlier Topline Readout
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focusing on SNS-101 Phase 1/2 Trial; Pausing Other Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Taking a Strike at VISTA With a Conditionally Active Monoclonal Antibody; Initiating Coverage With a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Sensei Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
|